Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

ConclusionThe results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy.

http://link.springer.com/10.1007/s13555-024-01143-x

Source: Dermatology and Therapy - April 13, 2024 Category: Dermatology Source Type: research